MetaCap

Enliven Therapeutics (ELVN) vs Organon (OGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enliven Therapeutics (ELVN) has outperformed Organon (OGN) over the past year, gaining 113.9% versus a gain of 92.9%. Over five years, ELVN leads with a +254.6% price change compared with -55.4% for OGN. Organon is the larger company by market cap ($3.65 billion vs $3.42 billion), about 1.1 times the size.

Organon pays a dividend yielding 0.58%, while Enliven Therapeutics does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELVN+113.93%OGN+92.92%
+192%+75%-41%
Nov 21, 20251 yearNov 20, 2026
ELVN+252.50%OGN-55.55%
+380%+138%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELVN versus OGN key metrics
MetricELVNOGN
Share price$46.53$13.89
Market cap$3.42B$3.65B
1-day change+0.26%-0.14%
YTD return+202.14%+93.72%
1-year return+113.93%+92.92%
5-year return+254.65%-55.38%
P/E ratio (TTM)—17.81
Forward P/E—3.81
EPS (TTM)$-1.69$0.78
Dividend yield0.00%0.58%
Annual dividend$0.00$0.08
Revenue (latest FY)—$6.22B
Revenue growth (YoY)—-2.92%
Net income (latest FY)$-103.69M$187.00M
Gross margin—53.30%
Net margin—3.01%
52-week high$62.32$13.94
52-week low$14.79$5.69
Distance from 52-week high-25.34%-0.36%
Analyst consensusstrong_buynone
Avg. price target upside+59.75%-25.63%
Average volume1.36M2.74M
Shares outstanding73.60M262.62M
Employees6510,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ELVN has outperformed OGN by 21.0 percentage points over the past year.

About Enliven Therapeutics

ELVN stock →

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

About Organon

OGN stock →

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees

ELVN vs OGN FAQ

Which is bigger, Enliven Therapeutics or Organon?

Organon (OGN) is larger, with a market capitalization of $3.65B compared with $3.42B for Enliven Therapeutics (ELVN).

Which stock has performed better over the past year, ELVN or OGN?

ELVN returned +113.93% over the past 12 months, compared with +92.92% for OGN (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Enliven Therapeutics or Organon?

Organon pays a dividend yielding 0.58%, while Enliven Therapeutics does not currently pay a regular dividend.

Are Enliven Therapeutics and Organon in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons